Kevin U. Stephens, Sr, JD, MD

Payer decision-makers discuss defining value among agents for unintended pregnancy, uterine fibroids, and endometriosis.

A panel of experts discuss treatment selection among contraceptive agents and evolving treatment strategies for uterine fibroids and endometriosis.

Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.

Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.

Kevin Stephens, Sr. MD, JD examines key drivers of healthcare utilization for women of childbearing years.

Steven McCarus, MD FACOG highlights the shift away from surgical treatment toward medical therapy in UF and endometriosis.

Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.

Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.

Closing out their discussion on glaucoma management, experts share practical advice for care providers and payers alike.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, provide insight on unmet needs and future directions for the treatment of wet AMD and DME.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; and Kevin U. Stephens, Sr., JD, MD, explore the role of faricimab in the current treatment landscape for wet AMD.

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years.

Expert panelists review the use of MIGS and other channel procedures in patients with glaucoma.

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, comment on safety and cost considerations for the uptake of anti-VEGF biosimilars such as ranibizumab and discuss the impact on the future treatment landscape for wet AMD.

A review of selective laser trabeculoplasty in glaucoma management, and when it is appropriate to consider as a treatment option.

A review of the novel sustained release approach with bimatoprost implants and how this is affecting glaucoma management.

Nicholas G. Anderson, MD, explores the use of a novel port delivery system with ranibizumab for the treatment of wet AMD.

Philip Niles, MD, MBA; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, discuss the clinical and economic implications of a delay in therapy for wet AMD and DME.

Panelists discuss the role of rho kinase inhibitors in glaucoma management respective to cost, efficacy, and ease of use.

Shared insight on the importance of patient adherence in glaucoma management, and how this is influenced by therapeutic regimens.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Nicholas G. Anderson, MD; and Jim Kenney, RPh, MBA, comment on managing the utilization of anti-VEGF agents for wet AMD and DME, including the impact of step edits on care.

Nicholas G. Anderson, MD, shares factors to consider when selecting an anti-VEGF agent for treatment of wet AMD and DME.

Expert perspectives on the factors that inform therapy selection when managing patients with glaucoma.

Experts debate the use of generic agents over branded therapy when managing patients with glaucoma.

Philip Niles, MD, MBA, leads a discussion on treatment approaches that are utilized with anti-VEGF agents in wet AMD and DME, including payer considerations for approaches such as treat and extend.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; and Kevin U. Stephens, Sr., JD, MD, provide insight on the anti-VEGF treatment landscape and options for patients with wet AMD and DME.

A broad review of therapeutic classes approved for the management of glaucoma and how they may be sequenced.

Following a brief discussion on utilization management, experts discuss the current paradigm of patient access to therapy.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, review goals of therapy for patients with wet age-related macular degeneration (AMD) and discuss a health plan perspective for the management of therapy.